Abstracts Archive - Page 1916 of 2425 - ACR Meeting Abstracts

Abstract Number: 2039 • 2014 ACR/ARHP Annual Meeting
Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi-Years before Clinical Onset (Pre-RA) Than in Non-RA Matched Control (CN) Subjects
Alfonse T. Masi, Azeem A. Rehman and Jean C. Aldag, Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Dysregulations in androgenic-anabolic (A-A) steroids and cytokines are recognized in RA and pre-RA subjects (Rheum Dis Clin N Am 2005; 31: 131-60). However, deviations…
Abstract Number: 2038 • 2014 ACR/ARHP Annual Meeting
Respiratory Cause Mortality Was Significantly Predicted By Incident Rheumatoid Arthritis (RA) and Higher Pre-RA Levels (0.50+ SD) of Soluble Interleukin-2 Receptor Alpha (sIL-2Rá): Results of a 21-Year Community-Based Cohort Survival Analysis
Alfonse T. Masi¹, Azeem Rehman¹, Huaping Wang¹ and Jean Aldag², ¹Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Medicine, University of Illinois College of Medicince at Peoria, retired, Peoria, IL
Background/Purpose: Interstitial lung disease (ILD) mortality is reported to be increased in RA (Bongartz T et al. A&R 2010; 62: 1583-91). However, non-malignant respiratory mortality…
Abstract Number: 2037 • 2014 ACR/ARHP Annual Meeting
Incidence and Prevalence of Myasthenia Gravis in Rheumatoid Arthritis Patients with and without Treatment Compared with the General Population
Neil Accortt¹, Mary Anthony¹, Jennifer Schenfeld², Travis Wheeling², Anna Hassebroek², Cynthia O'Malley¹ and Michael Sprafka¹, ¹Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA
Background/Purpose: There is a dearth of information on the incidence rate of myasthenia gravis (MG) in the US and specifically among rheumatoid arthritis (RA) patients. …
Abstract Number: 2036 • 2014 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with RA
Seoyoung C. Kim¹, Sebastian Schneeweiss², Jun Liu³, Elizabeth W. Karlson⁴, Jeffrey N. Katz⁵, Sarah Feldman² and Daniel H. Solomon⁶, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Human papillomaviruses (HPV) are causes of high-grade cervical dysplasia and cervical cancer. Persistent HPV infection, the major risk factor for cervical cancer, is associated…
Abstract Number: 2035 • 2014 ACR/ARHP Annual Meeting
Joint Distribution and Outcome in 350 Patients with Monoarthritis of Less Than 16 Weeks Duration: Data from a Multicenter Longitudinal Observational Study in Eastern Norway
Ellen Sauar Norli^1,2, Gina Hetland Brinkmann^1,3, Tore K. Kvien¹, Olav Bjørneboe⁴, Anne Julsrud Haugen³, Halvor Nygaard⁵, Cathrine Thunem⁶, Elisabeth Lie¹ and Maria Dahl Mjaavatten¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, ³Dept. of Rheumatology, Østfold Hospital Trust, Fredrikstad, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, ⁵Dept. of Rheumatology, Revmatismesykehuset Lillehammer, Lillehammer, Norway, ⁶Dept. of Rheumatology, Betanien Hospital, Skien, Norway
Background/Purpose: Cohort studies are essential to provide better understanding of the prognosis of acute monoarthritis, but few studies have focused on this issue. Our objective…
Abstract Number: 2033 • 2014 ACR/ARHP Annual Meeting
Patient Factors Associated with Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis
Rachel J. Black^1,2, Rebecca Joseph^2,3, Benjamin Brown⁴, Mohammad Movahedi², Mark Lunt⁵ and William G Dixon², ¹Department of Medicine, The University of Adelaide, Adelaide, Australia, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁴Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose Oral glucocorticoids (GCs) are commonly used in the treatment of rheumatoid arthritis (RA) and GC prescriptions are often issued in the primary care setting.…
Abstract Number: 2034 • 2014 ACR/ARHP Annual Meeting
A Treat-to-Target Strategy Preserves Work Capacity in Early Rheumatoid Arthritis (RA)
Mihir D. Wechalekar¹, Steve Quinn², Susan Lester³, Ella Shanahan⁴, Robert Metcalf⁵, E. Michael Shanahan⁶ and Susanna Proudman^4,7, ¹Flinders University School of Medicine, Adelaide, Australia, ²Flinders Clinical Effectiveness, Flinders University, Adelaide, Australia, ³Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, ⁴University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁵University of Adelaide, Adelaide, Australia, ⁶Rheumatology, Flinders University, Bedford Park, South Australia, Australia, ⁷Department of Rheumatology, Royal Adelaide Hospital, SA, Australia
Background/Purpose Historical data (1)indicate a third of patients with RA are unable to work within the first 5 years of diagnosis. Our aim was to…
Abstract Number: 2032 • 2014 ACR/ARHP Annual Meeting
Psychological Factors Predict Adherence to Methotrexate (MTX) in Rheumatoid Arthritis (RA); Findings from a Systematic Review of Rates, Predictors and Associations with Patient Outcomes
Holly Hope¹, James Bluett^1,2, Kimme Hyrich³, Lis Cordingley⁴ and Suzanne M. Verstappen³, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Methotrexate (MTX) is a first line therapy for Rheumatoid Arthritis (RA). Treatment response to MTX is not universal, and nonadherence may partially explain poor…
Abstract Number: 2030 • 2014 ACR/ARHP Annual Meeting
Predicting Failure of Conventional Disease Modifying Antirheumatic Drugs in Treatment Naive Early Rheumatoid Arthritis Patients: A Single Centre Inception Prognostic Factor Cohort Study
Mette Axelsen¹, Trine Bay Laurberg¹, Robin Christensen², Ulrich Fredberg³ and Torkell Ellingsen^4,5,6, ¹Silkeborg Hospital, Silkeborg, Denmark, ²Rheumatology, MSU, The Parker Institute, Copenhagen University Hospital, Frederiksberg, Denmark, ³Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, Silkeborg, Denmark, ⁴Department of Rheumatology, Odense University Hospital, Denmark, Odense, Denmark, ⁵The Danish National Registry DANBIO, Odense, Denmark, ⁶Diagnostic Centre Region, Hospital Silkeborg Denmark, Odense, Denmark
Background/Purpose Finding prognostic factors for treatment failure on synthetic disease modifying antirheumatic drugs (DMARD) in early treatment naive rheumatoid arthritis (RA) is a challenge. The…
Abstract Number: 2031 • 2014 ACR/ARHP Annual Meeting
Early Adherence to Methotrexate in Rheumatoid Arthritis (RA) Is High: a Prospective Longitudinal Study of New Users
Holly Hope¹, Kimme Hyrich², James Anderson¹, Lis Cordingley³ and Suzanne Verstappen², ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
Background/Purpose Methotrexate (MTX) is the recommended first-line DMARD for rheumatoid arthritis (RA) in most countries, however response is not universal. Non-adherence may explain this to…
Abstract Number: 2029 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-Sectional Study
Helga Radner^1,2, Kazuki Yoshida^3,4, Ihsane Hmamouchi⁵, Maxime Dougados^6,7, Josef Smolen⁸ and Daniel H Solomon⁹, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, Kamogawa, Japan, ⁴Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, ⁵Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ⁶Descartes University, Cochin Hospital, Paris, France, ⁷INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁸Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁹Rheumatology, Brigham and Women's Hospital, Boston, MA
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-sectional StudyBackground/Purpose The presence of multimorbidity could lead to less intensive treatment of RA.…
Abstract Number: 2028 • 2014 ACR/ARHP Annual Meeting
Effect of Age at Rheumatoid Arthritis Onset on Clinical, Radiographic, and Functional Outcomes: The Espoir Cohort
Thomas Krams¹, Adeline Ruyssen-Witrand², Delphine Nigon¹, Bruno Fautrel^3,4,5, Francis Berenbaum^6,7, Alain G. Cantagrel⁸ and Arnaud Constantin⁹, ¹Rhumatologie, Purpan University Hospital, Toulouse, France, ²Rheumatology, Purpan University Hospital, Toulouse, France, ³Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁴Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁵Rheumatology, Pitie Salpetriere Hospital, Paris, France, ⁶Service de Rhumatologie, Saint-Antoine Hospital, Paris, France, ⁷INSERM - UMR S 938, Paris, France, ⁸Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁹Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease with peak incidence in the fourth and fifth decades of age. To investigate whether age at disease…
Abstract Number: 2047 • 2014 ACR/ARHP Annual Meeting
No Association of Serum Uric Acid with Hip Fracture Risk in Older Men and Women from the Framingham Original Cohort
Shivani Sahni¹, Kelsey Mangano², Katherine Tucker³, Caroline Fox⁴, Douglas P. Kiel⁵, Xiaochun Zhang⁶ and Marian T. Hannan¹, ¹Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Clinical Laboratory & Nutritional Sciences, Center for Population Health & Health Disparities, University of Massachusetts, Lowell, MA, ⁴Institute of Genetics and Biophysics, NHLBI's Framingham Heart Study and Center for Population Studies, Framingham, MA, ⁵Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Musculoskeletal Research, Institute for Aging Research, Hebrew SeniorLife, Roslindale, MA
Background/Purpose: Serum uric acid (UA) has been linked with fractures in older men. Three different studies in older men showed conflicting results. The objective…
Abstract Number: 2046 • 2014 ACR/ARHP Annual Meeting
Perceived Discrimination in Individuals with Radiographic Knee and Hip Osteoarthritis
Rebecca J. Cleveland¹, Jordan B. Renner², Joanne M. Jordan³ and Leigh F. Callahan⁴, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina Department of Radiology, Chapel Hill, NC, ³University of North Carolina Dept of Epidemiology, Chapel Hill, NC, ⁴Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC
Background/Purpose To describe the characteristics of participants who reported feelings of discrimination among a cohort of participants with radiographic osteoarthritis (rOA) of the knee and/or…
Abstract Number: 2045 • 2014 ACR/ARHP Annual Meeting
Interaction Effects Between Genes and Blood Lead Level on a Composite Score of Multiple Joint Symptoms: The Johnston County Osteoarthritis Project
Youfang Liu¹, Amanda Nelson² and Joanne M. Jordan³, ¹Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ²5) Division of Rheumatology, Allergy, and Immunology and Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina Dept of Epidemiology, Chapel Hill, NC
Background/Purpose Previous studies suggested that blood lead level is associated with multiple joint symptoms. In this study, we conducted a Genome-Wide Gene-Environment Interactions analysis to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].